Sherief H. Gamie, MD, PhD, Author at Grand Rounds in Urology

Sherief H. Gamie, MD, PhD

Chief & Director Molecular Imaging and Theranostics Professor of Clinical Radiology (UCSD), University of California, San Diego

San Diego, California

Dr. Sherief H. Gamie, MD, PhD, is a Professor of Clinical Radiology and the Chief & Director Molecular Imaging and Theranostics at the University of California, San Diego, and is affiliated with multiple hospitals in the area. Dr. Gamie’s clinical interests include targeted applications of radiopharmaceuticals in cancer diagnosis and therapy.

Dr. Gamie earned his medical degree from the University of Alexandria Faculty of Medicine in 1990. Dr. Gamie’s research focuses on molecular imaging in cancer staging and targeted radiation therapy (brachytherapy & intravascular radiation therapy (IVRT)), and his work has been published in multiple peer-reviewed publications.

Dr. Gamie is a Board Certified Specialist with the American Board of Nuclear Medicine, and serves as Chair, Imaging Department and Medical Director, Nuclear Imaging/PET/CT at MemorialCare Long Beach Medical Center and Miller Children’s and Women’s Hospital in Long Beach, California.

Talks by Sherief H. Gamie, MD, PhD

Radiology & Theranostics in Castrate Resistant Prostate Cancer (CRPC)

Sherief H. Gamie, MD, PhD | Nov 2025

Dr. Sherief H. Gamie reviews PSMA-based imaging and radioligand therapy for mCRPC, emphasizing theranostic integration for diagnosis, treatment, and follow-up.

PET Tumor Board – Case 6: A Case of a 57-year-old with an Elevated PSA and Small Prostate Volume

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Nov 2025

A 57-year-old with favorable-intermediate risk prostate cancer illustrates PSMA PET/MRI interpretation, rib uptake pitfalls, and treatment selection.

Interpreting PSMA PET/CT Scan Reports

Sherief H. Gamie, MD, PhD and E. David Crawford, MD | Nov 2025

Dr. Gamie explains a stepwise method for reading prostate-specific membrane antigen positron emission tomography computed tomography reports, using standardized uptake value references and prior studies to separate physiologic, inflammatory, and pathologic findings.

PET Tumor Board Case 5: A Case of a 77-year-old Prostate Cancer Patient with Ulcerative Colitis and Uncertain PET Findings

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Aug 2025

Multidisciplinary case review shows how PSMA PET false positives can mimic nodal disease and alter prostate cancer management.

PET Tumor Board – Case 4: A Case of a 66-year old Male with Elevated PSA of 9.06 and MRI Showing PI-RADS Category 4 and 5

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Aug 2025

E. David Crawford, MD, and the panel discuss a case of a 66-year-old with elevated PSA, MRI PIRADS 5 lesion, and PSA density of 0.11.